Melanoma Clinical Trial

Boron Neutron Capture Therapy in Treating Patients With Melanoma

Summary

RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue.

PURPOSE: Phase II trial to study the effectiveness of boron neutron capture therapy in treating patients who have melanoma.

View Full Description

Full Description

OBJECTIVES:

Determine the clinical response, by serial objective measurements, in patients with melanoma treated with boron neutron capture therapy.
Determine the time course, uniformity, and severity of acute dermal reactions in patients treated with this regimen.
Determine the late dermal reactions in patients who are followed for at least 6 months after treatment with this regimen.
Determine the pharmacokinetics of this regimen in these patients.

OUTLINE: Patients are stratified according to tumor size (no greater than 15 cc vs greater than 15 cc).

Patients undergo boron neutron capture therapy.

Patients are followed for 3 years.

PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study within 3 years.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed melanoma
Evaluable disease

Lesion(s) to be irradiated must be located in 1 of the following areas:

On an extremity
On the head or neck (including the scalp)
In the subdermal lymphatics (excluding the proximal axilla)

Area to be irradiated must not exceed a maximum dimension of 10 cm

Maximum tumor depth from the surface of the skin cannot exceed 6 cm

PATIENT CHARACTERISTICS:

Age

18 and over

Performance status

ECOG 0-1

Life expectancy

More than 6 months

Hematopoietic

Not specified

Hepatic

Not specified

Renal

Creatinine normal

Cardiovascular

No history of severe cardiac disease
No uncontrolled arrhythmias or conduction defects
No unstable or newly diagnosed angina pectoris
No recent coronary artery disease
No congestive heart failure

Other

Not pregnant
Negative pregnancy test
No history of phenylketonuria
Must have sufficient mental competence

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

Not specified

Endocrine therapy

Not specified

Radiotherapy

No prior radiotherapy to study sites

Surgery

Not specified

Study is for people with:

Melanoma

Phase:

Phase 2

Study ID:

NCT00059800

Recruitment Status:

Completed

Sponsor:

Beth Israel Deaconess Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Beth Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States
Massachusetts Institute of Technology
Cambridge Massachusetts, 02139, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 2

Study ID:

NCT00059800

Recruitment Status:

Completed

Sponsor:


Beth Israel Deaconess Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider